Thomas S. McHugh Net Worth

The estimated Net Worth of Thomas S Mchugh is at least $1.82 Million dollars as of 16 January 2024. Mr Mchugh owns over 2,000 units of Avadel Pharmaceuticals plc stock worth over $1,098,825 and over the last 21 years he sold AVDL stock worth over $136,884. In addition, he makes $581,200 as Sr. VP & CFO at Avadel Pharmaceuticals plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr McHugh AVDL stock SEC Form 4 insiders trading

Mr has made over 8 trades of the Avadel Pharmaceuticals plc stock since 2005, according to the Form 4 filled with the SEC. Most recently he bought 2,000 units of AVDL stock worth $29,000 on 16 January 2024.

The largest trade he's ever made was buying 50,000 units of Avadel Pharmaceuticals plc stock on 27 May 2022 worth over $107,000. On average, Mr trades about 5,453 units every 402 days since 2003. As of 16 January 2024 he still owns at least 80,500 units of Avadel Pharmaceuticals plc stock.

You can see the complete history of Mr Mchugh stock trades at the bottom of the page.

Mr. Thomas S. McHugh biography

Thomas S. McHugh is the Sr. VP & CFO at Avadel Pharmaceuticals plc.

What is the salary of Mr McHugh?

As the Sr. VP & CFO of Avadel Pharmaceuticals plc, the total compensation of Mr McHugh at Avadel Pharmaceuticals plc is $581,200. There are 2 executives at Avadel Pharmaceuticals plc getting paid more, with Gregory J. Divis Jr. having the highest compensation of $897,000.

How old is Mr McHugh?

Mr McHugh is 56, he's been the Sr. VP & CFO of Avadel Pharmaceuticals plc since . There are no older and 3 younger executives at Avadel Pharmaceuticals plc.

What's Mr McHugh's mailing address?

Thomas's mailing address filed with the SEC is C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, L2, D02 T380.

Insiders trading at Avadel Pharmaceuticals plc

Over the last 8 years, insiders at Avadel Pharmaceuticals plc have traded over $7,791,038 worth of Avadel Pharmaceuticals plc stock and bought 775,568 units worth $4,366,224 . The most active insiders traders include Healthcare Master Fund Ltd ..., Kevin Broadfin Capital, Llc..., and Naseem Amin. On average, Avadel Pharmaceuticals plc executives and independent directors trade stock every 43 days with the average trade being worth of $381,436. The most recent stock trade was executed by Thomas S Mchugh on 16 January 2024, trading 2,000 units of AVDL stock currently worth $29,000.

What does Avadel Pharmaceuticals plc do?

avadel pharmaceuticals plc (nasdaq: avdl) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take, helping patients adhere to their prescribed medical treatment and see better results. avadel’s current portfolio of products and product candidates focuses on the urology, central nervous system (cns) / sleep, and hospital markets. the company is headquartered in dublin, ireland with operations in st. louis, missouri and lyon, france.

Complete history of Mr Mchugh stock trades at Avadel Pharmaceuticals plc and Huttig Building Products

Avadel Pharmaceuticals plc executives and stock owners

Avadel Pharmaceuticals plc executives and other stock owners filed with the SEC include:

• Gregory J. Divis Jr.,
  CEO & Director
• Dr. Jordan S. Dubow M.D.,
  Consultant
• Thomas S. McHugh,
  Sr. VP & CFO
• Angie Woods,
  VP of People & Culture
• Richard Kim,
  Chief Commercial Officer
• Dr. Jason M. Vaughn,
  Sr. VP of Technical Operations
• Steven G. Sullivan,
  VP of Sales & Marketing and Head of Commercial Operations
• Christian Kalita Pharm.D,
  Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs
• Séverine Martin,
  Director of HR and Corp. Projects
• Mark W. Elrod,
  VP of Sales
• Gregory J. Davis,
  VP of Corp. and Bus. Devel.
• Phillandas T. Thompson,
  See Remarks
• Marcus W Elrod,
  See Remarks
• David Monteith,
  See Remarks
• Healthcare Master Fund Ltd ...,
  
• Craig R Stapleton,
  Director
• Guillaume Cerutti,
  Director
• Michael F Kanan,
  See Remarks
• Christophe Navarre,
  Director
• Francis Fildes,
  Director
• Stephen G. Sullivan,
  See Remarks
• Scott A. Macke,
  See Remarks
• David P Gusky,
  See Remarks
• Jason Vaughn,
  Sr. VP, Technical Operations
• Mark Anthony Mc Camish,
  Director
• Healthcare Master Fund Ltd ...,
  
• Peter J. Thornton,
  Director
• Naseem Amin,
  Director
• Gregory J. Davis,
  See Remarks
• Dhiren D'silva,
  See Remarks
• James Edeerfield Management...,
  
• Assche Benoit Van,
  Director
• Geoffrey Michael Glass,
  Director
• Linda Palczuk,
  Director
• Michael S Anderson,
  Chief Executive Officer
• Kevin Broadfin Capital, Llc...,
  
• Eric J Ende,
  Director
• Thomas S Mchugh,
  Chief Financial Officer
• Jordan Dubow,
  Chief Medical Officer
• Richard J Kim,
  Chief Commercial Officer
• Gregory J Divis,
  Chief Executive Officer
• Douglas J Williamson,
  Chief Medical Officer